In contrast, in a metanalysis of 12 randomized, double-blind, placebo-controlled trials comprising 3065 of 73 238 participants (4.2%) with diabetes who were using GLP-1 RAs at baseline, SGLT2i reduced the risk of CKD progression in participants both receiving and not receiving GLP-1 RAs [HR 0.65 (95% CI 0.460.94) versus HR 0.67 (95% CI 0.620.72)
Building on that success, offering access to compounded GLP-1s gives medical providers and customers consistent and affordable access to effective, trusted and safe medications
Pay attention to changes over time
Not everyone, however, was persuaded by Marks and Samols' results
Conversely, as we discussed, if youre losing weight too fast, it might show you that your intake is way below TDEE and needs adjusting for safety